20 Dec, EOD - Indian

SENSEX 78041.59 (-1.49)

Nifty 50 23587.5 (-1.52)

Nifty Bank 50759.2 (-1.58)

Nifty IT 43771.05 (-2.63)

Nifty Midcap 100 56906.75 (-2.82)

Nifty Next 50 68702.65 (-2.72)

Nifty Pharma 22501.85 (-0.86)

Nifty Smallcap 100 18714.3 (-2.19)

20 Dec, EOD - Global

NIKKEI 225 38701.9 (-0.29)

HANG SENG 19720.7 (-0.16)

S&P 6008.5 (1.05)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(01 Oct 2024, 12:13)

Zydus Life’s Ahmedabad facility gets EIR from USFDA

Zydus Lifesciences announced that it has received the establishment inspection report (EIR) from the United States Food and Drug Administration (USFDA) for its transdermal patch manufacturing facility Pharmez, Ahmedabad.


The USFDA conducted an inspection from 15 to 19 July 2024, and has been classified as Voluntary Action Indicated (VAI).

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The pharma company’s consolidated net profit surged 30.64% to Rs 1,419.9 crore in Q1 FY25 as compared to Rs 1,086.9 crore posted in Q1 FY24. Revenue from operations jumped 20.77% year on year (YoY) to Rs 6,207.5 crore in the quarter ended 30 June 2024.

Shares of Zydus Lifesciences rose 0.12% to currently trade at Rs 1,069.60 on the BSE.

More News
More Company News View Company Information